Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy-Reference-Cited by-同舟云学术

Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy

Published:2017-02-24 Issue:6 Volume:47 Page:494-498
ISSN:0368-2811
Container-title:Japanese Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Shimada Takako¹,Saito Toshiaki¹,Shimokawa Mototsugu²,Shimamoto Kumi¹,Matsushita Shuhei¹,Yamaguchi Shinichiro¹,Ariyoshi Kazuya¹,Okadome Masao¹

Affiliation:

1. Gynecology Service, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka

2. C linical Research Institute, National Kyushu Cancer Center, 3-1-1 Notame, Fukuoka, Japan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://academic.oup.com/jjco/article-pdf/47/6/494/26427607/hyx026.pdf

Reference14 articles.

1. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer;Heintz;Int J Gynaecol Obstet,2006

2. Cyclophosphamide and cisplatin compered with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;New Engl J Med,1996

3. Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial;Ferrero;Ann Oncol,2007

4. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial;Mahner;Br J Cancer,2012

5. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J Clin Oncol,2006

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhanced biological activity of liposomal methylated resveratrol analog 3′-hydroxy-3,4,5,4′-tetramethoxystilbene (DMU-214) in 3D patient-derived ovarian cancer model;Drug Delivery;2022-07-27

2. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review);International Journal of Oncology;2021-06-14

3. Conditional Relative Survival of Ovarian Cancer: A Korean National Cancer Registry Study;Frontiers in Oncology;2021-04-28

4. Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau;CANCER REPORTS;2019-05-09

5. A scalable filtration method for high throughput screening based on cell deformability;Lab on a Chip;2019